General form of registration statement for all companies including face-amount certificate companies

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
SCHEDULE OF OTHER CURRENT ASSETS

Other current assets consisted of the following as of September 30, 2021 and December 31, 2020:

 SCHEDULE OF OTHER CURRENT ASSETS

    September 30, 2021     December 31, 2020  
    (unaudited)        
Lab supply inventory   $ 2,271     $ 2,052  
Prepaid expenses     734       625  
Other     130       45  
Total other current assets   $ 3,135     $ 2,722  

Other current assets consisted of the following as of December 31, 2020 and 2019:

 

    December 31, 2020     December 31, 2019  
Lab supply inventory   $ 2,052     $ 1,825  
Prepaid expenses     625       971  
Funds in escrow     -       888  
Other     45       167  
Total other current assets   $ 2,722     $ 3,851  
SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE

 SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE

                         
    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2021     2020     2021     2020  
    (unaudited)     (unaudited)  
Basic weighted average number of common shares     4,165       4,038       4,119       4,025  
Potential dilutive effect of stock-based awards     -       -       -       -  
Diluted weighted average number of common shares     4,165       4,038       4,119       4,025  
 
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2021     2020     2021     2020  
    (unaudited)     (unaudited)  
Options     684       878       684       878  
Restricted stock and restricted stock units (RSUs)     366       28       366       28  
Warrants     1,405       1,405       1,405       1,405  
      2,455       2,311       2,455       2,311  

The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 shares and the following outstanding stock-based awards and warrants were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands):

 

    Years Ended December 31,  
    2020     2019  
Options     849       416  
Restricted stock units (RSUs)     238       49  
Warrants     1,405       1,420  
      2,492       1,885